3 citations
,
May 2022 in “Journal of The American Academy of Dermatology” This source notes that while low-dose oral minoxidil is effective for treating androgenetic alopecia, it has been associated with electrocardiogram changes and palpitations even at low doses.
8 citations
,
January 2023 in “Biosensors” This review discusses recent progress in PENG-based sensors for non-invasive medical diagnosis and treatment but reports no new experimental results.
August 2025 in “Journal of Cosmetic Dermatology” In this study, Gupta et al. observed that pericardial effusions were dose-independently associated with oral minoxidil use for hypertension but not frequently reported during its use for alopecia, suggesting a potential underreporting issue and the need for standardized risk monitoring in alopecia treatment.
August 2026 in “LUMEN ET VIRTUS” In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.
September 2025 in “Journal of Medical Sciences and Health” This study observed that among men aged 18 to 35 with early onset androgenetic alopecia, those with severe grades and metabolic syndrome may face increased cardiovascular risks, highlighting the importance of screening and monitoring.